Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer | Synapse
July 15, 2024Open Access
Supplementary Figure S4 from Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Figure S4. Results of phase 1b clinical trial of SG and talazoparib